1.Sales and profit
See section β- Alterity Therapeutics Ltd had $1.2M of revenue in fiscal 2026, down 77.8% on the year before. Over five years, revenue changed β19.1% a year on average.
- Alterity Therapeutics Ltd lost $15.9M in fiscal 2026.
Alterity Therapeutics Ltd
ATHE Nasdaq Pharmaceutical Preparations Financials FY2017βFY2026
Alterity Therapeutics Ltd had $1.2M of revenue in fiscal 2026, down 77.8% on the year before. Over five years, revenue changed β19.1% a year on average.
Download report
3-page PDF: the company, its results and charts with peers.
KIRAβs summary AI analyst
Hi! I read Alterity Therapeutics Ltdβs latest annual report (fiscal 2026). Here is what stands out:
4 to watch
2.Cash and shareholders
See section β- Free cash flow was β$15.3M in fiscal 2026, β1,312.0% of revenue.
- No open-market insider trades in the last 12 months.
3.Financial health
See section β- Alterity Therapeutics Ltd passes 3 of 7 financial health tests (Piotroski F-score).
Alterity Therapeutics Ltd in 30 seconds
Good So-so Weak
Weak
Are sales growing?
β77.8%
No. Sales fell 77.8% last year.
Weak
Does it make a profit?
β1,363.1%
No. It lost money last year.
Weak
Does profit turn into cash?
β1,312.0%
No. It spent more cash than it brought in.
Weak
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2026
Market cap
Last close times the latest diluted share count, so it is approximate.
β
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Alterity Therapeutics Ltd did it, and the next one. Share prices often move a lot on those days.
Next results
August 27, 2027
Friday Β· in 305 days
- Time
- Before the market opens
- Covers
- Period ended Jun 30, 2027
- Source
- Stoqly estimate
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 28, 2026 | Period ended Jun 30, 2026 | Before the market opens | 20-F β |
| Aug 29, 2025 | Period ended Jun 30, 2025 | Time not announced | 20-F β |
| Sep 26, 2024 | Period ended Jun 30, 2024 | After the market closes | 20-F β |
| Aug 31, 2023 | Period ended Jun 30, 2023 | Before the market opens | 20-F β |
| Aug 31, 2022 | Period ended Jun 30, 2022 | During market hours | 20-F β |
| Sep 2, 2021 | Period ended Jun 30, 2021 | Before the market opens | 20-F β |
| Sep 15, 2020 | Period ended Jun 30, 2020 | Before the market opens | 20-F β |
| Aug 30, 2019 | Period ended Jun 30, 2019 | During market hours | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
Revenue and margins
KIRA Β· Alterity Therapeutics Ltd had $1.2M of revenue in fiscal 2026, down 77.8% on the year before. Over five years, revenue changed β19.1% a year on average.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY17
Revenue $0.1M
FY18
Revenue $0.2M
FY19
Revenue $3.6M
FY20
Revenue $0.1M
FY21
Revenue $3.4M
FY22
Revenue $3.7M
FY23
Revenue $2.6M
FY24
Revenue $2.8M
FY25
Revenue $5.2M
FY26
Revenue $1.2M
Margins, % of revenue
FY17
Gross β
Operating β
Net β5,697.9%
FCF β4,452.0%
FY18
Gross β
Operating β
Net β4,108.3%
FCF β3,135.1%
FY19
Gross β
Operating β
Net 243.8%
FCF β275.9%
FY20
Gross β
Operating β
Net 9,623.3%
FCF β6,756.4%
FY21
Gross β
Operating β
Net 339.8%
FCF β384.8%
FY22
Gross β
Operating β
Net 250.6%
FCF β242.4%
FY23
Gross β
Operating β
Net 351.1%
FCF β509.6%
FY24
Gross β
Operating β
Net β446.0%
FCF β294.1%
FY25
Gross β
Operating β
Net β150.2%
FCF β141.6%
FY26
Gross β
Operating β
Net β1,363.1%
FCF β1,312.0%
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Alterity Therapeutics Ltd lost $15.9M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY17
Net income β$5.7M
FY18
Net income β$6.4M
FY19
Net income $8.8M
FY20
Net income $9.0M
FY21
Net income $11.4M
FY22
Net income $9.3M
FY23
Net income $9.3M
FY24
Net income β$12.5M
FY25
Net income β$7.9M
FY26
Net income β$15.9M
Diluted EPS
FY17
Diluted EPS β$12.76
FY18
Diluted EPS β$14.41
FY19
Diluted EPS β$17.16
FY20
Diluted EPS β$12.06
FY21
Diluted EPS β$8.06
FY22
Diluted EPS β$4.61
FY23
Diluted EPS β$4.60
FY24
Diluted EPS β$4.09
FY25
Diluted EPS β$1.48
FY26
Diluted EPS β
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$15.3M in fiscal 2026, β1,312.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY17
Free cash flow β$4.4M
FY18
Free cash flow β$4.9M
FY19
Free cash flow β$10.0M
FY20
Free cash flow β$6.3M
FY21
Free cash flow β$12.9M
FY22
Free cash flow β$9.0M
FY23
Free cash flow β$13.5M
FY24
Free cash flow β$8.3M
FY25
Free cash flow β$7.4M
FY26
Free cash flow β$15.3M
Cash from operations vs capital spending
FY17
Cash from operations β$4.4M
Capital spending $0.0M
FY18
Cash from operations β$4.8M
Capital spending $0.0M
FY19
Cash from operations β$10.0M
Capital spending $0.0M
FY20
Cash from operations β$6.3M
Capital spending $0.0M
FY21
Cash from operations β$12.9M
Capital spending $0.0M
FY22
Cash from operations β$9.0M
Capital spending $0.1M
FY23
Cash from operations β$13.5M
Capital spending $0.0M
FY24
Cash from operations β$8.3M
Capital spending $0.0M
FY25
Cash from operations β$7.4M
Capital spending $0.0M
FY26
Cash from operations β$15.3M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY17
Dividends β
Buybacks β
FY18
Dividends β
Buybacks β
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
FY26
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY17
Diluted shares 0.04B
FY18
Diluted shares 0.04B
FY19
Diluted shares 0.05B
FY20
Diluted shares 0.07B
FY21
Diluted shares 0.14B
FY22
Diluted shares 0.20B
FY23
Diluted shares 0.20B
FY24
Diluted shares 0.30B
FY25
Diluted shares 0.53B
FY26
Diluted shares 0.02B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Alterity Therapeutics Ltd can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY17
Cash $16.8M
Debt β
FY18
Cash $11.3M
Debt β
FY19
Cash $10.1M
Debt β
FY20
Cash $6.3M
Debt β
FY21
Cash $21.1M
Debt β
FY22
Cash $23.9M
Debt β
FY23
Cash $10.5M
Debt β
FY24
Cash $8.4M
Debt β
FY25
Cash $21.7M
Debt β
FY26
Cash $25.7M
Debt β
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $23.9M | $10.5M | $8.4M | $21.7M | $25.7M |
| Current ratio | 7.1x | 6.2x | 3.5x | 13.0x | 14.5x |
| Quick ratio | 7.1x | 6.2x | 3.5x | 13.0x | 14.5x |
| Total assets | $28.5M | $18.1M | $12.8M | $30.1M | $31.7M |
| Total liabilities | $4.1M | $3.0M | $3.6M | $2.4M | $2.3M |
| Shareholders' equity | $24.4M | β$129M | β$143M | β$148M | $29.4M |
| Net debt (β = net cash) | β | β | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY17
Return on capital β
Return on equity β31.2%
Return on assets β29.3%
FY18
Return on capital β
Return on equity β42.6%
Return on assets β38.5%
FY19
Return on capital β
Return on equity 75.2%
Return on assets 63.5%
FY20
Return on capital β
Return on equity 109.3%
Return on assets 87.0%
FY21
Return on capital β
Return on equity 82.4%
Return on assets 71.5%
FY22
Return on capital β
Return on equity 39.5%
Return on assets 34.8%
FY23
Return on capital β
Return on equity β
Return on assets 39.9%
FY24
Return on capital β
Return on equity β
Return on assets β81.1%
FY25
Return on capital β
Return on equity β
Return on assets β36.7%
FY26
Return on capital β
Return on equity β
Return on assets β51.4%
Return on capital
Return on equity
Return on assets
Piotroski F-score
KIRA Β· Alterity Therapeutics Ltd passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 3 / 7 | 2 / 7 | 3 / 7 | 1 / 7 | 3 / 7 | 2 / 7 | 3 / 7 | 3 / 7 |
| Accruals ratio | β6.5% | β9.4% | 135.4% | 147.9% | 152.4% | 68.1% | 97.8% | β27.7% | β2.1% | β1.9% |
| Altman Z'' | β | β | β | β | β | β | β | β | β | β |
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.1M | $0.2M | $3.6M | $0.1M | $3.4M | $3.7M | $2.6M | $2.8M | $5.2M | $1.2M |
| Net interest income | β | β | β | β | β | β | β | $0.2M | $0.3M | $1.2M |
| Research and development | $4.3M | $5.2M | $9.3M | $6.8M | $9.2M | $10.7M | $8.9M | $12.2M | $9.3M | $11.9M |
| Interest expense | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Pretax income | β$5.7M | β$6.4M | β$8.8M | β$9.0M | β$11.4M | β$9.3M | β$9.2M | β$12.5M | β$7.8M | β$15.8M |
| Income tax | $0.0M | $0.0M | $0.0M | β | β | $0.1M | $0.1M | $0.0M | $0.0M | $0.1M |
| Net income | β$5.7M | β$6.4M | $8.8M | $9.0M | $11.4M | $9.3M | $9.3M | β$12.5M | β$7.9M | β$15.9M |
| Net income to common | β | β | $8.8M | $9.0M | $11.4M | $9.3M | $9.3M | β | β | β |
| Diluted EPS | β$12.76 | β$14.41 | β$17.16 | β$12.06 | β$8.06 | β$4.61 | β$4.60 | β$4.09 | β$1.48 | β |
| Diluted shares | 0.04B | 0.04B | 0.05B | 0.07B | 0.14B | 0.20B | 0.20B | 0.30B | 0.53B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | β$4.4M | β$4.8M | β$10.0M | β$6.3M | β$12.9M | β$9.0M | β$13.5M | β$8.3M | β$7.4M | β$15.3M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | β$4.4M | β$4.9M | β$10.0M | β$6.3M | β$12.9M | β$9.0M | β$13.5M | β$8.3M | β$7.4M | β$15.3M |
| Stock-based compensation | β | β | β | β | $1.5M | $1.1M | $0.7M | $0.6M | $0.6M | $3.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $16.8M | $11.3M | $10.1M | $6.3M | $21.1M | $23.9M | $10.5M | $8.4M | $21.7M | $25.7M |
| Current assets | $19.4M | $13.8M | $13.9M | $6.7M | $25.1M | $28.3M | $17.9M | $12.7M | $30.0M | $31.6M |
| Current liabilities | $1.2M | $2.0M | $2.3M | $1.9M | $2.3M | $4.0M | $2.9M | $3.6M | $2.3M | $2.2M |
| Property and equipment, net | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | $19.4M | $13.8M | $13.9M | $6.8M | $25.2M | $28.5M | $18.1M | $12.8M | $30.1M | $31.7M |
| Total liabilities | $1.2M | $2.0M | $2.4M | $1.9M | $2.3M | $4.1M | $3.0M | $3.6M | $2.4M | $2.3M |
| Shareholders' equity | $18.2M | $11.9M | $11.6M | $4.9M | $22.8M | $24.4M | β$129M | β$143M | β$148M | $29.4M |
| Margins | ||||||||||
| Net margin | β5,697.9% | β4,108.3% | 243.8% | 9,623.3% | 339.8% | 250.6% | 351.1% | β446.0% | β150.2% | β1,363.1% |
| FCF margin | β4,452.0% | β3,135.1% | β275.9% | β6,756.4% | β384.8% | β242.4% | β509.6% | β294.1% | β141.6% | β1,312.0% |
| Net interest share of revenue | β | β | β | β | β | β | β | 6.3% | 5.5% | 100.0% |
| Returns | ||||||||||
| Return on equity | β31.2% | β42.6% | 75.2% | 109.3% | 82.4% | 39.5% | β | β | β | β |
| Return on assets | β29.3% | β38.5% | 63.5% | 87.0% | 71.5% | 34.8% | 39.9% | β81.1% | β36.7% | β51.4% |
| Return on tangible equity | β31.2% | β53.9% | 76.1% | 184.0% | 50.0% | 38.2% | β | β | β | β53.9% |
| Growth | ||||||||||
| Revenue growth | β | 56.2% | 2,220.7% | β97.4% | 3,487.9% | 10.6% | β28.9% | 6.3% | 86.2% | β77.8% |
| Net income growth | β | β | β | 2.2% | 26.7% | β18.4% | β0.4% | β235.0% | β | β |
| Share count change | β | 0.0% | 15.3% | 45.3% | 89.6% | 41.8% | 0.9% | 50.3% | 75.3% | β96.7% |
| Financial health | ||||||||||
| Current ratio | 15.9x | 7.1x | 6.0x | 3.6x | 10.9x | 7.1x | 6.2x | 3.5x | 13.0x | 14.5x |
| Quick ratio | 15.9x | 7.1x | 6.0x | 3.6x | 10.9x | 7.1x | 6.2x | 3.5x | 13.0x | 14.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 21.0% | 31.0% | 0.1% | 12.0% | 0.2% | 1.7% | 0.2% | 0.1% | 0.0% | 0.0% |
| Stock comp / revenue | β | β | β | β | 43.3% | 29.4% | 24.6% | 20.6% | 12.1% | 261.7% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 2.0 | 3.0 | 1.0 | 3.0 | 2.0 | 3.0 | 3.0 |
| Accruals ratio | β6.5% | β9.4% | 135.4% | 147.9% | 152.4% | 68.1% | 97.8% | β27.7% | β2.1% | β1.9% |
Source: SEC EDGAR XBRL filings (CIK 0001131343). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in AUD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. Per-share figures are per US-listed share (1 ADS = 12 ordinary shares). For information only β not investment advice. Check the original filings before relying on any figure.